Wednesday, July 8, 2026

Drug profile · INN

loxapine

loxapine (ADASUVE) is a serotonin 2a (5-ht2a) receptor antagonist. Route of administration: inhalation. Current US regulatory status: approved.

FDA: approved EMA: approved Nervous system (N05) N05AH01
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — loxapine
US status
approved
Class
Nervous system (N05)
Route
INHALATION
Patents
0
Programs
1
Data quality
0.84

Quick answer

loxapine (ADASUVE) is a serotonin 2a (5-ht2a) receptor antagonist. Route of administration: inhalation. Current US regulatory status: approved.

Key facts

INN loxapine
Brand ADASUVE
Mechanism Serotonin 2a (5-HT2a) receptor antagonist
Target D2-like dopamine receptor
Therapeutic class Nervous system (N05)
Route INHALATION
Formulation POWDER
ATC code N05AH01

Mechanism of action

Serotonin 2a (5-HT2a) receptor antagonist

Primary target: D2-like dopamine receptor

Approval history

Authority Status Date
FDA approved
EMA approved

Pipeline programs

  1. ADASUVE® Phase 1 · Teva Pharma · BiPolar

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. brivaracetam Nervous system (N03)
  4. bupivacaine Nervous system (N01)
  5. buprenorphine Nervous system (N07)
  6. caffeine citrate Nervous system (N06)

Frequently asked questions

What is loxapine?

loxapine (ADASUVE) is a serotonin 2a (5-ht2a) receptor antagonist. Route of administration: inhalation. Current US regulatory status: approved.

What is the brand name for loxapine?

ADASUVE is a marketed brand name for loxapine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of loxapine?

loxapine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.